Artiva Biotherapeutics
ARTV
40 hedge funds and large institutions have $108M invested in Artiva Biotherapeutics in 2026 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 3 increasing their positions, 12 reducing their positions, and 5 closing their positions.
140% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 5
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
49% more capital invested
Capital invested by funds: $72.7M → $108M (+$35.7M)
18% more funds holding
Funds holding: 34 → 40 (+6)
0.97% less ownership
Funds ownership: 69.08% → 68.11% (-0.97%)
75% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBM
Propel Bio Management
Los Angeles,
California
|
+$724K |
| 2 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$152K |
| 3 |
VCIM
Velan Capital Investment Management
Alpharetta,
Georgia
|
+$124K |
| 4 |
SAM
Simplify Asset Management
Las Vegas,
Nevada
|
+$115K |
| 5 |
SA
Sanctuary Advisors
Indianapolis,
Indiana
|
+$107K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VP
venBio Partners
San Francisco,
California
|
-$580K |
| 2 |
Millennium Management
New York
|
-$464K |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$341K |
| 4 |
Renaissance Technologies
New York
|
-$179K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$175K |
ARTV Hedge Fund Activity: Q1 2026 in Review
40 of the 8,134 institutional investors tracked by Wall St. Rank reported a position in Artiva Biotherapeutics (ARTV) for Q1 2026, worth a combined $108M — up 49% from $72.7M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new ARTV positions and 5 closed out — a net gain of 7 holders — while 3 added to existing stakes and 12 trimmed.
The largest buyer was Propel Bio Management, opening a new position worth an estimated $724K. The largest seller was venBio Partners, cutting an estimated $580K.
- 40 institutional investors held Artiva Biotherapeutics (ARTV) as of Q1 2026, up from 34 in Q4 2025.
- Funds reported $108M of Artiva Biotherapeutics stock for Q1 2026, up 49% quarter-over-quarter.
- 12 funds opened new Artiva Biotherapeutics positions in Q1 2026 and 5 closed out, a net change of +7 holders.
- The largest Artiva Biotherapeutics buyer in Q1 2026 was Propel Bio Management, an estimated $724K added.
- The largest Artiva Biotherapeutics seller in Q1 2026 was venBio Partners, an estimated $580K sold.
Based on aggregated 13F filings for Q1 2026.